Resources

Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.

Innovate UK has announced an investment over £14 million across 29 innovative projects to help make the UK’s medicines manufacturing sector more sustainable.

Brainomix has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology.

Axplora unveils a €50 million investment at its Mourenx site, strengthening its role in producing next-generation therapies, including GLP-1 drugs for diabetes and obesity.

Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally.

hVIVO plc announces that it has successfully completed a pilot characterisation study for its human metapneumovirus (hMPV) strain A2 challenge agent, demonstrating proof-of-concept for a future hVIVO hMPV challenge model to test new vaccines and antivirals.

Plexāā, a London-based medical device startup, is thrilled to announce a new partnership with Panasonic Manufacturing UK as their contract manufacturer for the award-winning BLOOM⁴³ medical device.

Stablepharma and AJ Vaccines have established the primary commercial distribution deal with proposed terms, in relation to the distribution and commercialisation of the SPVX02 (Td) in Europe.

Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.

When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.  

UCL’s Policy Impact Unit, who work closely with researchers in VaxHub Sustainable, VaxHub Global and the FTHM Hub, have recently published a position paper.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

In this guest blog, Luis Lacerda and Suzanne Farid from UCL explore the transformative potential of engineering biology and its critical role in addressing sustainability challenges in medicines manufacturing.

The North West of England is recognised as one of the cornerstones of the UK’s life sciences  sector. This enduring strength positions the North West as a hub of national significance for life sciences manufacturing.

Quotient Sciences announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), a modular, integrated, and automated RNA-micro factory which enables the end-to-end production of various RNA-based products.

Pension reform unlocks cash for UK life sciences, London Life Sciences Week and #bioProcessUK are here.

Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has established a UK subsidiary, based on the Oxford Science Park, as the company continues its development into an international leader in food allergies.